In one of the research, CD133+ specific peptide TISWPPR (TR) modified NLC (T-NLC) were prepared in order to target cancer cells along with cancer stem cells (CSCs) simultaneously as an effective therapeutic approach. The gene discussed is PROM1; the disease is cancer.